Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing Rafael NYSE: RFL reported ...

Rafael's Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing Rafael NYSE: RFL reported top-line results from its pivotal Phase III TransportNPC study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C, a rare, progressive genetic disorder. The company said it remains on track to submit a New Drug Application to the U.S. Food and Drug Administration in the fourth quarter of 2026.